Jonathan S. Wolin - 11 Dec 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Reporting relationship: Chief of Staff, Chief Compliance Officer & General Counsel
Issuer ticker: JAGX
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:30:27 UTC
Prior SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan S. Wolin

Key filing fact

Jonathan S. Wolin filed Form 4 for Jaguar Health, Inc. (JAGX) on 21 Jan 2026.

Key facts

This page summarizes Jonathan S. Wolin's Form 4 filing for Jaguar Health, Inc. (JAGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 16:30.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001787587 Primary reporting owner

Wolin Jonathan S.

Relationship: Chief of Staff, Chief Compliance Officer & General Counsel
Address: C/O JAGUAR HEALTH, INC., 200 PINE ST., STE 400, SAN FRANCISCO
Signature: /s/ Jonathan S. Wolin
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAGX transaction

Common Stock

Award

Transaction value: $0
Shares: +11,740
Change %: +5929%
Price: $0.000000
Shares after: 11,938
Date: 11 Dec 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JAGX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +11,740
Change %
Price: $0.000000
Shares after: 11,740
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,740
Exercise price: $1.44
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Granted pursuant to the issuer's 2014 Stock Incentive Plan.

Footnote F2

The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.

Footnote F4

On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

Footnote F5

The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

SEC remarks

Chief of Staff, Chief Compliance Officer & General Counsel